Gyre Therapeutics Announces Alignment with China’s CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting

Gyre Pharmaceuticals completed a Pre-NDA meeting with China’s CDE, which agreed that the existing Phase 3 clinical data support a conditional ...
TipRanks on MSN

GNI Group’s F351 secures path toward conditional approval and priority review in China

GNI Group ( ($JP:2160) ) just unveiled an update. GNI Group announced that its subsidiary Gyre Therapeutics has completed a Pre-New Drug ...
American BankerOpinion

De novo national banks face a new road map to OCC approval

Conditional approval of a national bank charter used to be a virtual guarantee that an institution would open its doors. But ...